title: Combined administration of PHCCC, a positive allosteric modulator of mGlu4 receptors and ACPT-I, mGlu III receptor agonist evokes antidepressant-like effects in rats.
abstract: Numerous pharmacological data indicate involvement of glutamate, the major excitatory neurotransmitter in the brain, in the pathophysiology of several neuropsychiatric disorders. It was shown in the preclinical studies that compounds which can reduce the excess of glutamate release (for example group III metabotropic receptors agonists) possess potential therapeutic properties. Thus we focused our interests on (-)-N-phenyl-7-(hydroxyimino) cyclopropa[b]chromen-1a-carboxamide (PHCCC), which is a positive allosteric modulator of mGlu4 receptor. We examined the potential antidepressant-like activity of PHCCC after injection into the brain ventricles alone, or together with (1S,3R,4S)-1-aminocyclo-pentane-1,3,4-tricarboxylic acid (ACPT-I), a nonselective group III mGlu receptor agonist, using the forced swimming test (FST) in rats. We found that ACPT-I induced a dose dependent antidepressant-like effect in FST, which was blocked by an antagonist of group III mGlu receptors (RS)-alpha-cyclopropyl-4-phosphonophenylglycine (CPPG). PHCCC injected intracerebroventricular was not effective, however when the compound was administered together with non-effective dose of ACPT-I, a profound antidepressant-like activity in FST was demonstrated. This effect was reversed by CPPG, group III mGlu receptors antagonist. Results of our studies indicate that a combined administration positive allosteric modulation of mGlu4 receptor and agonists of group III mGlu receptors may be a promising target in the future treatment of depressive disorder.
authors.affiliation: Department of Neurobiology, Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland.
authors.forename: K
authors.initials: K
authors.lastname: Kłak
authors.forename: A
authors.initials: A
authors.lastname: Pałucha
authors.forename: P
authors.initials: P
authors.lastname: Brański
authors.forename: M
authors.initials: M
authors.lastname: Sowa
authors.forename: A
authors.initials: A
authors.lastname: Pilc
mesh_terms: D000495:Allosteric Site; D000818:Animals; D000928:Antidepressive Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001522:Behavior, Animal / Q000187:drug effects; D001578:Benzopyrans / Q000008:administration & dosage* / Q000737:chemistry*; D001921:Brain / Q000187:drug effects; D002220:Carbamazepine / Q000737:chemistry*; D003517:Cyclopentanes / Q000378:metabolism*; D003863:Depression; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D018094:Receptors, Metabotropic Glutamate / Q000819:agonists* / Q000737:chemistry / Q000378:metabolism*; D013550:Swimming; D014233:Tricarboxylic Acids / Q000378:metabolism*
chemical_list: C409063:1-aminocyclopentane-1,2,4-tricarboxylic acid; D000928:Antidepressive Agents; D001578:Benzopyrans; D003517:Cyclopentanes; C442478:N-phenyl-7-(hydroxyimino)cyclopropa(b)chromen-1a-carboxamide; D018094:Receptors, Metabotropic Glutamate; D014233:Tricarboxylic Acids; C102718:metabotropic glutamate receptor 3; D002220:Carbamazepine; C108823:metabotropic glutamate receptor 4